Concordance of two approaches in monitoring of minimal residual disease in B-precursor acute lymphoblastic leukemia: Fusion transcripts and leukemia-associated immunophenotypes.

Background/purpose: Real-time quantitative polymerase chain reaction (RQ-PCR) for fusion transcripts and flow cytometry for leukemia-specific markers are widely used for minimal residual disease (MRD) detection in acute lymphoblastic leukemia, but the relation between the results of either method is...

Descripción completa

Detalles Bibliográficos
Publicado en:Journal of the Formosan Medical Association Vol. 116; no. 10; pp. 774 - 782
Autores principales: Huang, Ying-Jung, Coustan-Smith, Elaine, Kao, Hsiao-Wen, Liu, Hsi-Che, Chen, Shih-Hsiang, Hsiao, Chih-Cheng, Yang, Chao-Ping, Jaing, Tang-Her, Yeh, Ting-Chi, Kuo, Ming-Chung, Lai, Chang-Liang, Chang, Chia-Hui, Campana, Dario, Liang, Der-Cherng, Shih, Lee-Yung
Formato: Journal Article
Publicado: Elsevier B.V. Oct2017
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=125175919&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 125175919
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        09296646
        3O8P
      jtl: Journal of the Formosan Medical Association
      issn: 09296646
      maglogo: N
    pubinfo:
      dt: Oct2017
      vid: 116
      iid: 10
      pid: 467
      pub: Elsevier B.V.
      place: New York, New York
    artinfo:
      ui:
        125175919
        125175919
        NLM28063722
        10.1016/j.jfma.2016.12.002
        NLM28063722
        125175919
      ppf: 774
      ppct: 8
      formats:
      tig:
        atl: Concordance of two approaches in monitoring of minimal residual disease in B-precursor acute lymphoblastic leukemia: Fusion transcripts and leukemia-associated immunophenotypes.
      aug:
        au:
          Huang, Ying-Jung
          Coustan-Smith, Elaine
          Kao, Hsiao-Wen
          Liu, Hsi-Che
          Chen, Shih-Hsiang
          Hsiao, Chih-Cheng
          Yang, Chao-Ping
          Jaing, Tang-Her
          Yeh, Ting-Chi
          Kuo, Ming-Chung
          Lai, Chang-Liang
          Chang, Chia-Hui
          Campana, Dario
          Liang, Der-Cherng
          Shih, Lee-Yung
        affil: Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan
      sug:
        subj:
          Neoplastic Processes Pathology
          Leukemia, Lymphocytic, Acute Diagnosis
          Proteins
          Leukemia, Lymphocytic, Acute
          Regression
          Immunophenotyping
          Acute Disease
          Bone Marrow Pathology
          Flow Cytometry
          Polymerase Chain Reaction
          Questionnaires
      ab: Background/purpose: Real-time quantitative polymerase chain reaction (RQ-PCR) for fusion transcripts and flow cytometry for leukemia-specific markers are widely used for minimal residual disease (MRD) detection in acute lymphoblastic leukemia, but the relation between the results of either method is unclear.Methods: Mononucleated cells from 108 bone marrow samples collected from 55 B-precursor acute lymphoblastic leukemia patients (30 with t(12;21)/ETV6-RUNX1, 16 with t(9;22)/BCR-ABL1 and nine with t(1;19)/TCF3-PBX1) were examined in tandem by RQ-PCR and six-color flow cytometry.Results: MRD results were concordant in 91 of the 108 paired samples (84.2%; K=0.690); 49 samples were MRD-negative while 42 were MRD-positive by both methods, with < 1 log difference in positive MRD estimates in 39 samples (92.9%). Of the 17 discordant samples, 16 were MRD-positive by RQ-PCR but MRD-negative by flow cytometry; the opposite was true in one sample. Kappa value/concordance was 0.690/85.0% (n = 60) for ETV6-RUNX1, 0.842/93.3% (n = 15) for TCF3-PBX1, and 0.535/78.8% (n = 33) for BCR-ABL1. Specific immunophenotypic abnormalities were more prevalent in each genetic subgroup, such as CD38 underexpression, CD58 overexpression, and CD34 overexpression in ETV6-RUNX1, TCF3-PBX1, and BCR-ABL1, respectively.Conclusion: In most follow-up samples, MRD estimates by two methods are in agreement, especially in patients with TCF3-PBX1.
      pubtype: Academic Journal
      doctype: Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N